DALRD3 Inhibitors
DALRD3 Inhibitors are a diverse set of compounds that indirectly attenuate the functional activity of DALRD3 through various intracellular signaling pathways and regulatory mechanisms. PI3K inhibitors such as LY 294002 and Wortmannin lead to decreased AKT phosphorylation, which in turn could diminish the functional activity of DALRD3, assuming DALRD3 operates downstream of AKT. The inhibition ofmTOR by Rapamycin also contributes to this effect by disrupting downstream pathways that may involve DALRD3. In parallel, the MAPK pathway, which plays a critical role in cell proliferation and survival, can be modulated by compounds such as SB 203580, U0126, and PD98059; these compounds inhibit p38 and MEK, respectively, thereby potentially reducing DALRD3 activity if it is interconnected with these signaling routes. Additionally, SP600125's inhibition of JNK and Y-27632's inhibition of ROCK could decrease DALRD3 activity by influencing apoptotic signaling and cytoskeletal organization, respectively, provided that DALRD3 is implicated in these cellular processes.
Further modulation of DALRD3 function is achieved through epigenetic and cell cycle regulation. Compounds like 5-Azacytidine and Trichostatin A, which affect DNA methylation and histone deacetylation, respectively, could lead to altered DALRD3 expression and activity if DALRD3 is subject to epigenetic control. Alsterpaullone's inhibition of cyclin-dependent kinases may also impinge upon DALRD3 function by disrupting cell cycle-related processes that DALRD3 might be involved in. Lastly, Thapsigargin's disruption of calcium homeostasis could play a key role in inhibiting DALRD3 if its activity relies on calcium signaling, by altering the intracellular calcium concentration. Collectively, these inhibitors offer a multifaceted approach to diminishing the activity of DALRD3 by targeting distinct but potentially interconnected biochemical pathways and processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of PI3K, LY294002 decreases PI3K activity leading to reduced AKT phosphorylation. Since DALRD3 is implicated in pathways that are downstream of AKT signaling, inhibition of PI3K could diminish DALRD3's functional activity by reducing the phosphorylation and subsequent activation of proteins that may interact with or regulate DALRD3. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another potent and irreversible inhibitor of PI3K. Similar to LY294002, it prevents AKT activation. The reduction in AKT activity can indirectly decrease DALRD3 function, as DALRD3 might function downstream of AKT-mediated signaling processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor, Rapamycin blocks the mTORC1 pathway, which is known to affect several downstream proteins including those potentially interacting with DALRD3. By inhibiting mTORC1, Rapamycin could decrease the functional activity of DALRD3 if DALRD3 operates within this pathway or its related networks. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK can alter the stress response and apoptotic signaling pathways. If DALRD3 is involved in these pathways or is regulated by stress response elements, then inhibition by SB203580 could indirectly reduce DALRD3 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
MEK1/2 inhibitor, U0126, can prevent the activation of the ERK pathway, a major signaling route affecting cell proliferation and survival. If DALRD3 is part of a cascade that relies on ERK signaling, U0126-mediated inhibition could result in diminished activity of DALRD3. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Like U0126, PD 98059 is a MEK inhibitor that blocks ERK phosphorylation. By suppressing this pathway, PD98059 could indirectly lead to a decrease in DALRD3 functional activity if DALRD3 is regulated by or associated with the ERK signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 can influence apoptotic and immune response pathways. As DALRD3 may have a role in these pathways, its activity could be indirectly reduced through JNK inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
A ROCK inhibitor, Y-27632 reduces the activity of Rho-associated kinases which are involved in cytoskeletal organization. If DALRD3 has a role in cytoskeletal arrangement or cell motility that involves ROCK, its functional activity could be diminished by Y-27632. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
As an inhibitor of DNA methyltransferases, 5-Azacytidine can cause DNA demethylation. If the expression of DALRD3 is epigenetically regulated, the use of 5-Azacytidine could lead to changes in its expression and hence functional activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor, Trichostatin A changes chromatin structure and affects gene expression. If DALRD3 expression is affected by histone acetylation, this inhibitor could diminish its functional activity by altering gene expression patterns. | ||||||